KOSDAQBiotech & Pharma304360

S.Biomedics

₩17,560▲ 0.29%2026-11-18 close
Market Cap
₩219.2B
Turnover
₩200M
Volume
10K
Shares out.
12.5M
PER
—
PBR
8.3×
EPS
-₩988
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales rising, losses persisting: a clinical-stage biotech

S.Biomedics is growing revenue through its medical device business, but operating losses have run for four straight years and for five straight quarters. Whether its Parkinson's cell therapy TED-A9 files a U.S. Phase 3 IND is the next key variable.

  1. 1

    Sales reached KRW 16.5 billion in 2025, up 20.5% from the prior year, and have risen for three straight years since 2023. Most of the growth came from medical device products such as dermal fillers.

  2. 2

    The 2025 operating loss was KRW 8.34 billion, with an operating margin of -50.4%, the largest loss year within 2022 to 2025.

  3. 3

    Third-quarter 2026 sales were KRW 3.74 billion and the operating loss was KRW 2.85 billion, narrower than the prior quarter but wider than a year earlier.

  4. 4

    In April 2026 the company disclosed about KRW 40 billion in new funding, consisting of KRW 17.8 billion in convertible preferred shares and KRW 22.2 billion in convertible bonds. The company said the bonds carry no interest and no refixing clause.

  5. 5

    TED-A9 released 24-month follow-up topline data in June 2026, and the company is targeting a U.S. FDA IND submission within 2026.

02

Business structure

S.Biomedics develops cell therapies based on embryonic and adult stem cells and listed on KOSDAQ in May 2023.

Its business has two pillars: a cell therapy pipeline that includes the Parkinson's candidate TED-A9, the FECS-Ad treatment for critical limb ischemia, and the TED-N spinal cord injury candidate, and a medical device and cosmetics business run through its consolidated subsidiary Estepharm.

Based on 2025 segment figures compiled from company disclosures, medical device products such as fillers generated KRW 15.52 billion, medical device goods such as lifting products KRW 1.01 billion, and stem cell products KRW 0.09 billion, so about 99.9% of consolidated revenue came from the device segment.

Stem cell product sales fell from KRW 0.59 billion in 2024 to KRW 0.09 billion in 2025, leaving cell therapy a small share of current revenue. Parent-only sales were just KRW 19.03 million in the first half of 2026, so most revenue is booked through the subsidiary.

Export growth has been cited as a driver of device sales. On the cell therapy side, the company was selected as a participating institution in a 2026 Ministry of Health and Welfare program, a two-and-a-half-year Korea-U.S. joint study with government support of KRW 7 billion.

The project applies CRISPR gene editing to embryonic stem cells and extends research toward neurodegenerative diseases such as multiple system atrophy and Alzheimer's disease.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3.2B-₩1.9B−59.4%
2025Q4₩4B-₩2.7B−66.4%
2026Q1₩4.4B-₩3B−68.0%
2026Q2₩4.8B-₩3.7B−76.5%
2026Q3₩3.7B-₩2.8B−76.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩12.1B-₩3.7B-₩6.3B−30.9%—2253.3%
2023₩13.1B-₩6B-₩7.5B−45.7%−108.5%160.3%
2024₩13.7B-₩5.4B-₩5.8B−39.6%−49.1%143.6%
2025₩16.5B-₩8.3B-₩8.1B−50.4%−93.6%146.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

Annual results show sales growth alongside persistent losses. Revenue rose from KRW 12.1 billion in 2022 to KRW 13.1 billion in 2023 (up 8.2%), KRW 13.7 billion in 2024 (up 4.8%), and KRW 16.5 billion in 2025 (up 20.5%).

Over the same period the operating loss was KRW 3.75 billion, KRW 5.99 billion, KRW 5.45 billion and KRW 8.34 billion, with operating margins of -30.9%, -45.7%, -39.6% and -50.4%.

Reports on the first half of 2026 cite R&D spending of KRW 7.4 billion, equal to 80.5% of sales for the period, as a factor keeping losses from narrowing. Net loss attributable to controlling shareholders was KRW 6.33 billion in 2022, KRW 7.52 billion in 2023, KRW 5.82 billion in 2024 and KRW 8.12 billion in 2025.

The debt-to-equity ratio fell from 2,253.3% in 2022 to 146.4% in 2025, but at year-end 2025 controlling shareholders held KRW 8.68 billion of KRW 16.7 billion total equity, so the rest is non-controlling interest.

Operating cash flow was negative in all four years, at -KRW 3.21 billion, -KRW 6.15 billion, -KRW 3.5 billion and -KRW 3.98 billion.

Quarterly sales rose to KRW 4.03 billion in the fourth quarter of 2025 (up 24.3% from the prior quarter), then to KRW 4.4 billion and KRW 4.82 billion in the first and second quarters of 2026, before falling 22.4% to KRW 3.74 billion in the third quarter, still up 15.1% year on year.

The operating loss peaked at KRW 3.69 billion in the second quarter of 2026 and narrowed to KRW 2.85 billion in the third quarter.

The second-quarter 2026 net loss attributable to controlling shareholders of KRW 6.84 billion was the largest of the five quarters, and the four-quarter total from the fourth quarter of 2025 to the third quarter of 2026 is KRW 12.9 billion.

In the fourth quarter of 2025 the operating loss was KRW 2.68 billion while the controlling-shareholder net loss was only KRW 501 million, a wide gap between the two measures.

05

Industry analysis

In Parkinson's disease, a string of failures among non-cell-based disease-modifying candidates has drawn more attention to cell therapy. A 2026 report noted that large global pharmaceutical companies including Roche, Biogen and UCB have had setbacks in clinical trials of non-cell treatments.

Among direct competitors, Bemdaneprocel from Bayer's subsidiary Blue Rock Therapeutics is in a multicenter, double-blind Phase 3 trial and holds the lead position.

In March 2026, Sumitomo Pharma received conditional approval in Japan for an allogeneic iPSC-derived therapy, opening another commercialization path for cell therapies.

S.Biomedics is pursuing U.S. clinical entry for TED-A9 on the basis of 24-month follow-up data, but it trails the leading competitor at the U.S. trial stage.

On the domestic regulatory side, a partial amendment to the Advanced Regenerative Bio Act that would widen the scope of embryonic stem cell therapies was introduced on March 30, 2026 and referred to the National Assembly's Health and Welfare Committee.

Passage could open a domestic commercialization route, which is the basis of the market's expectations. Competition in the device business depends on filler pricing and export competition.

The cell therapy pipeline has completed Phase 1/2a studies and is moving toward a later-stage trial, so regulatory approval and clinical results matter more than near-term demand.

06

Outlook

The most direct near-term goal is a U.S. FDA IND submission for TED-A9. At the BIO USA event in June 2026, the company shared 24-month follow-up topline results and began seeking global partners, and it said it aims to file a commercial-stage IND within 2026.

For U.S. manufacturing it is transferring technology to the global CDMO Catalent, and it said follow-on steps such as selecting a CRO will continue.

On safety, the company emphasized that no adverse events causally linked to TED-A9 had been reported up to 24 months after transplant, and it reported improvements in motor function and brain imaging indicators.

It also said it plans to pursue Japanese regulatory pre-consultation with PMDA in parallel to accelerate global expansion. On funding, the company plans to direct the KRW 40 billion raised in April 2026 mainly to TED-A9 clinical development in Korea and abroad.

Research scope has widened beyond Parkinson's disease toward neurodegenerative diseases more broadly, following a 2026 government-supported program, and two new Ministry of Science and ICT basic research projects are being used for Alzheimer's research.

Whether and when the FDA clears the IND is outside the company's control. As the expansion proceeds, R&D costs may rise further, so the trend in R&D spending and operating losses in upcoming periodic reports is an important point to watch.

07

Valuation

PER
—
PBR
8.3×
ROE
-76.4%
EPS
-₩988
BPS
₩2,266
Dividend per share
₩0

Because the company has posted net losses over the last four quarters, its price-to-earnings ratio cannot be calculated, so earnings-based multiples cannot be used for comparison and sales and book value must be considered instead.

The price-to-book ratio sits well above 1, a large premium to net asset value, which suggests the share price reflects expectations for the pipeline more than the balance sheet. The company pays no dividend, so its dividend yield is low relative to the sector average.

The debt-to-equity ratio improved sharply from 2,253.3% in 2022 to 146.4% in 2025, and the convertible preferred shares are recognized as equity rather than debt, which has been cited as a factor in the balance sheet improvement.

However, both the preferred shares and the convertible bonds can convert into common shares, so dilution is possible, and conversion of the preferred shares becomes available from April 22, 2027.

Because a large part of the company's value rests on pipeline expectations, multiples alone do not explain the share price, and clinical and regulatory events may weigh on valuation more than current earnings do.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Accumulating clinical data

The 24-month topline data reported no adverse events causally linked to TED-A9 up to 24 months after transplant, along with improvements in motor function and brain imaging indicators. The 12-month results were published in Cell in October 2025. Analysts see the long-term safety data as potentially useful support in the U.S. IND review.

Expanded financial capacity

In April 2026 the company raised about KRW 40 billion through KRW 17.8 billion of convertible preferred shares and KRW 22.2 billion of convertible bonds. Tiger Asset Management invested about KRW 25.1 billion on its own, and Dongkook Pharmaceutical, a long-time investor, also took part in the preferred share offering. The company plans to direct the proceeds to TED-A9 clinical development.

Revenue growth and an existing sales base

Sales grew from KRW 12.1 billion in 2022 to KRW 16.5 billion in 2025 and have risen for three straight years since 2023. Most 2025 revenue came from medical device products. Reports describe this sales base as helping to partly fund cell therapy R&D.

09

Bear factors

Persistent loss structure

Operating losses ran for four straight years from 2022 to 2025, and the 2025 operating margin was -50.4%. Losses have continued for five straight quarters, and the four-quarter net loss attributable to controlling shareholders totals KRW 12.9 billion. The second-quarter 2026 loss of KRW 6.84 billion was the largest of the five quarters.

No internal cash generation

Operating cash flow was negative in every year from 2022 to 2025. Reports on the first half of 2026 put R&D spending at KRW 7.4 billion, equal to 80.5% of sales. Parent-only sales are negligible, so most revenue depends on the subsidiary.

Clinical uncertainty and dilution

TED-A9 has not yet cleared a U.S. IND, while the leading global competitor is already running Phase 3 trials. The convertible preferred shares and bonds can convert into common stock, leaving dilution as an ongoing factor. Any delay in the clinical timeline could prolong cash burn.

10

Risk factors

Clinical and regulatory risk

The timing of the U.S. IND submission and approval is outside the company's control. Even with long-term data, a U.S. Phase 3 trial requires separate study design and regulatory discussions.

The domestic amendment on embryonic stem cell therapies was introduced in March 2026 and remains under National Assembly review, so its passage and scope could change the domestic commercialization path.

Financial and dilution risk

Operating losses and negative operating cash flow continue. Bondholders can request early redemption of the convertible bonds from April 22, 2028, which could become a cash outflow. Conversion of the preferred shares becomes possible from April 22, 2027, so dilution for existing shareholders could materialize.

Concentration and subsidiary dependence

Most 2025 consolidated revenue came from the device segment, while cell therapy product sales were only KRW 0.09 billion. Parent-only sales are negligible, so consolidated results depend heavily on subsidiary Estepharm.

Controlling shareholders held KRW 8.68 billion of KRW 16.7 billion total equity at year-end 2025, so the subsidiary ownership structure reduces the share attributable to the parent's shareholders.

11

What to watch next

  1. Within 2026

    Whether and when the TED-A9 IND is submitted to the U.S. FDA. A submission would mark the first formal step toward U.S. commercial-stage trials.

  2. Through the end of 2026, while under National Assembly review

    The Health and Welfare Committee's review of the partial amendment to the Advanced Regenerative Bio Act, which determines the domestic scope for embryonic stem cell therapies.

  3. After January 2027

    Fourth-quarter 2026 results, a quarter not yet in the disclosed figures. The point to check is whether the operating and controlling-shareholder losses continue the trend of the last five quarters.

  4. By March 31, 2027

    The 2026 annual business report, the next periodic filing, which will show full-year sales, operating loss, operating cash flow and the use of funds.

  5. From April 22, 2027

    The date from which conversion of the preferred shares can be requested. The scale of conversion and share price movement will determine the extent of dilution.

12

Overall view

S.Biomedics is growing its top line on the back of its device subsidiary, with 2025 sales of KRW 16.5 billion, up for three straight years. However, operating losses have run for four straight years since 2022 and for five straight quarters, so internal cash generation has not yet been established.

The company secured about KRW 40 billion in April 2026, which provides funding for TED-A9's U.S. clinical preparations.

Bullish points are the 24-month long-term safety data and the size of the recent financing, while bearish points are the loss structure, negative operating cash flow and the dilution potential of convertible securities. The pipeline's outcome depends on U.S.

IND clearance and subsequent clinical results, which the company only partly controls. The outcome of the domestic amendment will also shape the domestic route for cell therapies.

The next points to watch are whether the IND is submitted within 2026 and the trend in R&D spending and operating losses in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. needinfo.co.kr
  2. biobookmedia.com
  3. etoday.co.kr
  4. app.rndcircle.io
  5. the-stock.kr
  6. m.news.nate.com
  7. ibtomato.com
  8. ibtomato.com
  9. m.news.nate.com
  10. v.daum.net
  11. newsway.co.kr
  12. m.news.nate.com
  13. m.news.nate.com
  14. m.news.nate.com
  15. newsway.co.kr
  16. thebell.co.kr
  17. mt.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis